"Microdosing" is not a clinical term in testosterone therapy. It does not appear as a treatment concept in the Endocrine Society guideline, which frames dosing around a target — mid-normal concentrations — rather than around a schedule.[1]
Searched in the medical literature, the phrase surfaces largely in anti-doping detection research, where it describes small repeated doses used to evade testing. That is a different subject with a different purpose.
What people actually mean by it
Giving a smaller amount more often rather than a larger amount less often — daily or near-daily instead of weekly or longer. The total may be similar; what changes is how it is divided.
So the real question is not "is microdosing better?" It is: does dose frequency matter, and to what?
Where the evidence sits
On dose: well characterised. Across five weekly doses, fat-free mass, strength, hemoglobin and IGF-I rose with concentration while HDL fell — and sexual function, mood and cognition did not change significantly at any dose.[2] Different androgen-dependent processes have different dose-response relationships.[2]
On frequency: thin. No trial randomises men to the same weekly total delivered daily versus weekly and measures patient outcomes. Claims that one schedule produces better symptom control are extrapolation from pharmacokinetics, not findings from outcome trials.
On formulation: acknowledged but unquantified. The standard time-course review attributes the variation it documents in part to "pharmacodynamics of the testosterone preparation"[3] — an explicit statement that delivery shapes the effect profile, offered without a comparison.
Why the term persists
Because the reasoning is intuitive and the reports are real. Men on longer-interval injections describe feeling different across the cycle, and the dose-response data supply a plausible mechanism: if effects track concentration, and concentration varies, effects may vary.
What does not follow automatically is that any particular schedule fixes it, or by how much.
What the guideline actually says about choosing
Aim at mid-normal with any of the approved formulations, taking into account patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden and cost.[1]
Pharmacokinetics is on that list — the consideration is legitimate. So are four other things, including treatment burden. And compliance is one of the four items the guideline asks clinicians to monitor,[1] which makes "a schedule you will keep" a clinical variable rather than a preference.
Frequently asked questions
Is microdosing safer? No trial evidence establishes that. The risks needing monitoring — hematocrit above all — are driven substantially by dose and individual factors.[4]
Does it mean a lower total dose? Not necessarily. The term describes division, not total. Your total is set by the target.[1]
Why is it everywhere in marketing? It describes a real difference in administration and sounds precise. Treat it as a description of a schedule, not a claim about outcomes.
Should I ask about dose frequency? Yes — it is on the guideline's list.[1] Frame it as a fit question, not a search for a superior protocol.
Next in this series
The comparison most often made is injection against transdermal. It deserves the same scrutiny.
Continue with injection vs transdermal.
References
4 sources
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
- Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685. doi:10.1530/EJE-11-0221 · PMID 21753068
- Agrawal P, Singh SM, Kohn T. Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide. Eur Urol Focus. 2023;9(1):20–21. doi:10.1016/j.euf.2022.10.008 · PMID 36335038
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.